Screener / SEC EDGAR /CIK 0001704292 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Zai Lab Ltd ZLAB

Compare with peers Embed
Planned sales, announced before they happen

4 trading plans running, 38 Form 144 notices for $13.6M

10-Q, 10-K and Form 144
Plans running now 4 F. Ty Edmondson, William Lis, Richard Gaynor, Rafael Amado
Plans adopted 16 reported since May 9, 2023 Form 144 notices 38 $13.6M the sellers expected to sell

What ZLAB's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Nov 22, 2024 to Sep 16, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
F. Ty Edmondson
Chief Legal Officer and Corporate Secretary
Adopted 10b5-1 plan Sep 16, 2026 10-Q Nov 5, 2026
What the company wrote
On September 16, 2026, F. Ty Edmondson, the Company’s Chief Legal Officer and Corporate Secretary, adopted a new written Rule 10b5-1 trading arrangement for (1) the sale of ADSs up to $300,000 and (2) the sale of up to 12,500 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than September 16, 2027.
William Lis
director
Adopted 10b5-1 plan Aug 11, 2026 10-Q Nov 5, 2026
What the company wrote
On August 11, 2026, William Lis, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 23,048 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than September 16, 2027.
Richard Gaynor
directors
Adopted 10b5-1 plan Dec 16, 2025 10-K Feb 26, 2026
What the company wrote
On December 16, 2025, Richard Gaynor, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the purchase of ADSs with a price of up to $99,000. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 31, 2026.
Rafael Amado
President and Head of Global Research and Development
Adopted 10b5-1 plan Nov 14, 2025 10-K Feb 26, 2026
What the company wrote
On November 14, 2025, Rafael Amado, the Company’s President and Head of Global Research and Development, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 20,000 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 17, 2026.
Dr. Samantha (Ying) Du
Founder, Chief Executive officer, and Chairperson of the Board
Adopted 10b5-1 plan Nov 10, 2025 10-K Feb 26, 2026
What the company wrote
On November 10, 2025, Dr. Samantha (Ying) Du, the Company’s Founder, Chief Executive officer, and Chairperson of the Board, adopted a new written Rule 10b5-1 trading arrangement, for (1) the acquisition and sale of up to 400,000 ADSs upon the exercise of previously awarded options that are scheduled to expire in 2026 and (2) for the acquisition of up to 261,092 ADSs upon the exercise of previously awarded options that are scheduled to expire in 2026. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 9, 2026.
F. Ty Edmondson
Chief Legal Officer and Corporate Secretary
Adopted 10b5-1 plan Sep 12, 2025 10-Q Nov 6, 2025
What the company wrote
On September 12, 2025, F. Ty Edmondson, the Company’s Chief Legal Officer and Corporate Secretary, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 42,065 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 13, 2026.
William Lis
director
Adopted 10b5-1 plan Sep 10, 2025 10-Q Nov 6, 2025
What the company wrote
On September 10, 2025, William Lis, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 15,547 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than September 14, 2026.
William Lis
directors
Adopted 10b5-1 plan Mar 4, 2025 10-Q May 8, 2025
What the company wrote
On March 4, 2025, William Lis, one of the Company’s directors, amended his written Rule 10b5-1 trading arrangement adopted on November 20, 2024. Mr. Lis increased the number of shares to be sold pursuant to the plan by 2,125 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than June 1, 2026.
Yajing Chen
Chief Financial Officer
Adopted 10b5-1 plan Mar 3, 2025 10-Q May 8, 2025
What the company wrote
On March 3, 2025, Yajing Chen, the Company’s Chief Financial Officer, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 15,494 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than March 4, 2026.
F. Ty Edmondson
Chief Legal Officer
Adopted 10b5-1 plan Nov 22, 2024 10-K Feb 27, 2025
Rafael Amado
President and Head of Global Research and Development
Adopted 10b5-1 plan Nov 22, 2024 10-K Feb 27, 2025
Dr. Samantha (Ying) Du
Founder, Chief Executive officer, and Chairperson of the Board
Adopted 10b5-1 plan Nov 20, 2024 10-K Feb 27, 2025
William Lis
director
Adopted 10b5-1 plan Nov 20, 2024 10-K Feb 27, 2025
Richard Gaynor
director
Adopted 10b5-1 plan Jun 6, 2024 10-Q Aug 6, 2024
What the company wrote
On June 6, 2024, Richard Gaynor, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the disposition of up to 5,000 of the Company’s ADSs, each representing ten of the Company’s ordinary shares, to cover tax obligations in connection with the vesting of a previously granted restricted stock award. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than July 7, 2025.
Joshua Smiley
President and Chief Operating Officer
Ended plan May 13, 2024 10-Q Nov 7, 2023
What the company wrote
On August 12, 2023, Joshua Smiley, the Company’s President and Chief Operating Officer, adopted a new written Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K), for the purchase of up to 15,000 of the Company’s ADSs, each representing ten of the Company’s ordinary shares. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than May 13, 2024.
William Lis
director
Adopted 10b5-1 plan Feb 23, 2024 10-Q May 8, 2024
What the company wrote
On February 23 , 2024, William Lis, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the disposition of up to 10,397 of the Company’s ADSs, each representing ten of the Company’s ordinary shares, to cover tax obligations in connection with the vesting of a previously granted restricted stock award . This Rule 10b5-1 trading arrangement is scheduled to terminate no later than July 31, 2024.
Rafael Amado
President and Head of Global Oncology Research and Development
Adopted 10b5-1 plan Dec 15, 2023 10-K Feb 27, 2024
What the company wrote
On December 15, 2023, Rafael Amado, the Company’s President and Head of Global Oncology Research and Development, adopted a new written Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K), for the sale of up to 94,500 of the Company’s ADSs, each representing ten of the Company’s ordinary shares. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 16, 2024.
Show the other 9 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 16 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Aug 20, 2026 Smiley Joshua L
Former Officer
98,653 $2.6M
Aug 19, 2026 Chen Yajing
Officer
260 $7K
Aug 12, 2026 Lis William
Director
8,506 $213K
Aug 11, 2026 Chen Yajing
Officer
619 $15K
Jun 30, 2026 Du Ying
Officer, Director
7,026 $130K
Jun 26, 2026 Chen Yajing
Officer
2,264 $40K
Jun 26, 2026 Edmondson Frazor Titus III
Officer
4,103 $72K
Jun 26, 2026 Du Ying
Officer, Director
24,543 $429K
Jun 22, 2026 Lis William
Director
7,040 $127K
May 18, 2026 Du Ying
Officer, Director
50,000 $976K
May 15, 2026 Du Ying
Officer, Director
50,000 $1.0M
May 14, 2026 Du Ying
Officer, Director
50,000 $1.0M
May 14, 2026 Edmondson Frazor Titus III
Officer
3,517 $71K
May 13, 2026 Du Ying
Officer, Director
50,000 $960K
Apr 6, 2026 Smiley Joshua L
Officer
3,017 $62K
Apr 6, 2026 Du Ying
Officer, Director
2,653 $54K
Apr 6, 2026 Edmondson Frazor Titus III
Officer
1,224 $25K
Apr 6, 2026 Amado Rafael
Officer
2,739 $56K
Apr 6, 2026 Chen Yajing
Officer
853 $17K
Apr 2, 2026 Amado Rafael
Officer
9,910 $202K
Apr 2, 2026 Du Ying
Officer, Director
5,576 $114K
Apr 2, 2026 Smiley Joshua L
Officer
9,614 $196K
Apr 2, 2026 Edmondson Frazor Titus III
Officer
4,194 $86K
Apr 2, 2026 Chen Yajing
Officer
5,199 $106K
Mar 13, 2026 Edmondson Frazor Titus III
Officer
1,281 $24K
Mar 13, 2026 Smiley Joshua L
Officer
1,966 $37K
Mar 13, 2026 Amado Rafael
Officer
2,957 $55K
Mar 13, 2026 Chen Yajing
Officer
1,703 $32K
Mar 11, 2026 Du Ying
Officer, Director
1,067 $20K
Mar 9, 2026 Du Ying
Officer, Director
50,000 $960K
Mar 6, 2026 Du Ying
Officer, Director
50,000 $959K
Mar 5, 2026 Edmondson Frazor Titus III
Officer
15,569 $297K
Mar 5, 2026 Du Ying
Officer, Director
50,000 $953K
Mar 4, 2026 Du Ying
Officer, Director
50,000 $914K
Mar 3, 2026 Amado Rafael
Officer
10,000 $174K
Dec 31, 2025 Amado Rafael
Officer
10,787 $188K
Dec 16, 2025 Edmondson Frazor Titus III
Officer
8,651 $148K
Nov 21, 2025 Edmondson Frazor Titus III
Officer
14,328 $283K
Show the other 30 notices

From the Form 144 XML filed with the SEC, since Nov 21, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ZLAB/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.